ArticleCancer immunology, immunotherapy : CII1994
Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.
Article in Cancer immunology, immunotherapy : CII, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Pooled it
- Effect of silkworm pupae (Frontiers in pharmacology · 2023Article
- Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.International journal of clinical oncology · 2019Article
- Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer.World journal of gastrointestinal oncology · 2019Article
- TFrontiers in oncology · 2019Review
- Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer.Psychosomatic medicine · 2018Article
- Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.Medical oncology (Northwood, London, England) · 2013Article
- A gender-related action of IFNbeta-therapy was found in multiple sclerosis.Journal of translational medicine · 2012Article
- Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer.Clinical & developmental immunology · 2011Article
- Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.Clinical and experimental immunology · 2007Article
- Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum.Cancer immunology, immunotherapy : CII · 2007Article
- Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome.Cancer immunology, immunotherapy : CII · 2003Article
- Cell surface molecules and their prognostic values in assessing colorectal carcinomas.Annals of surgery · 2000Review
- Relation between depression and circulating immune products in patients with advanced colorectal cancer.Journal of the Royal Society of Medicine · 1998Article
- Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.British journal of cancer · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soluble interleukin-2 receptor (sIL-2R) levels have been found to be elevated in several clinical conditions, including disseminated solid neoplasms, whereas they are generally within the normal range in patients with locally limited neoplastic disease. The aim of the present study was to examine this in our colon cancer patients, and to assess if this situation can affect the in vitro activation of peripheral blood mononuclear cells (PBMC), examining the proliferative response to IL-2 and anti-CD3 monoclonal antibody, the IL-2 serum levels and the PBMC phenotype. The results show that sIL-2R levels were significantly correlated with the stage of the disease, showing an increase from stage I to stage IV; moreover, it is worth noting that the proliferative response to IL-2 plus anti-CD3 is significantly higher than to IL-2 alone in stage IV, without significant alteration in the numerical presence of T and natural killer cells. So it seems that in the peripheral blood of patients, connected with the disease progression, are present cellular populations showing a different response to activation, and that T cells acquire a better response condition than NK. Thus, since the T cellular population includes the tumour-specific cytotoxic precursor cells, this should be helpful for its tumour regressive activity, but it is conceivable that this population cannot perform its functions, owing to a deficiency in responsiveness of the specific ThCD4+ subpopulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.